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Abstract 
 
Purpose of the study: Define recommendations and estimate the value of anti-VEGF therapy 
applied during cataract surgery or in perioperative period in patients with AMD or DR. 
Procedures: A query was created and applied in PubMed. The found articles were then selected 
according to inclusion and exclusion criteria. 
Results: All patients presented VA improvement after surgery. Patients undergoing adjuvant 
anti-VEGF injection when subject to cataract surgery, presented lower ME incidence in a group 
with preoperative NPDR without ME, statistically significant better VA with CMT decrease in 
a group with preoperative NPDR and ME and no increase of exudation after surgery in a group 
with preoperative wet AMD. 
Conclusions: We recommend the use of bevacizumab as adjuvant treatment in patients with 
DR or wet AMD undergoing cataract surgery. 
Message of the paper: Anti-VEGF plays an important role as an adjuvant treatment in cataract 
surgery. 
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Introduction 
Cataract extraction with intra-ocular lens implantation is a common procedure that in 
patients without retinal pathology is known to increase visual acuity (VA) and by that life 
quality. 
Pathologies of the posterior chamber of the eye, such as age related macular 
degeneration (AMD) and diabetic retinopathy (DR), have high prevalence and often coexist in 
patients with cataracts. For that reason, it is common to see these patients being subject to 
cataract extraction, arising concerns whether surgery, even an uneventful one [1], could worsen 
retinal diseases, compromising visual acuity outcomes. Despite the existence of many studies 
addressing this subject, controversy remains whether these pathologies really worsen after 
surgery. 
Some studies relating cataract surgery with DR reported increased risk of progression 
[2, 3] however others simply stated that this progression was the result from natural course of 
disease [3-9]. In a review summarizing recent prospective studies outcomes [3], authors 
concluded that there is an increased risk of worsening for patients with severe non-proliferative 
diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR), as well as an increased 
risk of development and persistence of macular edema (ME) if present prior to surgery or in 
patients with severe NPDR. However, patients with diabetes but without DR, with mild-to-
moderate NPDR or without ME prior to surgery showed no increased risk of progression or 
incidence of DR or ME. 
In what concerns AMD progression after cataract extraction, all persists even more 
controversial. Some suggest a relation between cataract surgery and late AMD [10, 11], others 
found an association with early AMD [12] and others found no relation between surgery and 
progression of AMD [13]. Confusion factors such as coexistence of both diseases in elderly 
populations and presence of comorbidities (cardiovascular disease, hypertension) that may 
aggravate both diseases, persist until today making data interpretation more difficult. [14]. A 
recent review [15] about this question remain inconclusive but suggest that cataract surgery 
increases VA without an increased risk of progression to exudative AMD. 
Nevertheless, it is known that patients undergoing cataract extraction are subject to an 
aggression that consequently causes inflammation by liberation of inflammatory mediators 
such as prostaglandins and vascular endothelial growth factor (VEGF). These mediators, 
particularly VEGF, were shown to be increased in aqueous humour after cataract surgery [14] 
and in patients with PDR or wet AMD [15-18]. Consequently, VEGF may be a key mediator 
to aggravation of retinal pathologies after cataract extraction, acting mainly by increasing 
retinal vessel permeability [19]. In this context, it is important to assess whether in these patients 
anti-VEGF adjuvant treatments minimize retinal disease risk of progression and by that 
promote maximal visual acuity improvement. 
There are three different anti-VEGF agents with different characteristics and costs 
(aflibercept, bevacizumab and ranibizumab) in ophthalmologic clinical practice. Some of them 
were developed with eye treatment in mind, while others were developed for a different purpose 
(metastatic cancers) and were then adapted to off-label intra-ocular use (bevacizumab). Despite 
that, all seem to have similar efficacy and safety in retinal pathologies management, however 
with discrepant prices [16]. Bevacizumab is significantly cheaper than the other two drugs. 
However, there are no studies comparing each of these agents as adjuvant drugs in cataract 
surgery, reason why there is no clear indication of each of them is the best in this context.  
This article reviews the combination of cataract surgery with adjuvant intravitreal anti - 
VEGF injection in patients with DR and AMD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
 
The objective of this article is to define recommendations and estimate the value of anti 
VEGF therapy applied during cataract surgery or in perioperative period in patients with AMD 
or DR. 
The following query was used in PubMed data base: ("Cataract Extraction"[Mesh] OR 
"Cataract Extraction"[All Fields] OR cataract surgery OR phacoemulsification surgery) AND 
(bevacizumab OR Ranibizumab OR aflibercept OR pegaptanib OR Avastin OR Lucentis OR 
Eylea OR Macugen OR anti-vascular endothelial growth factor OR anti-VEGF OR 
intraoperative Intravitreal injection). 
The found articles were subject to inclusion and exclusion criteria, first in their titles 
and in case of doubts in their abstracts. After this selection, we searched the full text of the 
remaining articles using Endnote® (Version X7.2.1). The selected articles with full text 
accessibility were fully analyzed and used for writing this review.  
 
Inclusion Criteria Exclusion Criteria 
Study includes patients with AMD or DR (a
ny stage) undergoing cataract surgery and tr
eated with anti-VEGF drugs during surgery 
or in perioperative period. 
Study refers to patients without AMD or DR 
Study refers to other adjuvant treatments 
Single case report 
Study published over 10 years 
Study in other language than English or 
Portuguese 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
After performing a search on PubMed, 175 articles were found. Of these, according to 
the methodology described above, 16 were included and 159 were excluded. The included 
articles were then divided according to pathology (diabetic retinopathy and age related macular 
degeneration) and fully read. 
The studies regarding diabetic retinopathy were then further divided depending on grade 
of macular disease at the preoperative period. As result, three groups were created, dividing 
patients without macular edema (ME) (group 1), patients with ME (group 2) and patients with 
PDR or severe NPDR (group 3).  
In group 1 we identified three prospective randomized studies that are summarized in 
table 1 [17-19]. In these studies, patients undergoing surgery with intraoperative injection 
(intervention group (IG)) show best corrected visual acuity (BCVA) improvement, however 
without significant difference compared with patients that did not receive intraoperative anti -
VEGF injection (control group (CG)). Moreover, no differences in DR progression were also 
found between groups. Nevertheless, IG presented a decreased ME incidence as well as a 
central macular thickness (CMT) tendency to decrease. [17, 18]. Study [18] used bevacizumab 
and studies [17, 19] used ranibizumab in IG. 
Group 2 included five studies divided into two prospective randomized studies, one 
prospective case series, one retrospective nonrandomized study and one case report. Detailed 
characteristics were summarized in table 2 [20-24]. Selected studies in this group presented 
significant improvement of visual acuity after surgery [1, 20-22, 24, 25]. However, significantly 
greater increase in visual acuity was seen in the IG [22-24] in which all patients were injected 
with bevacizumab. In what concerns central macular thickness (CMT), control groups show a 
significant increase when compared to preoperative values [22-24], and intervention groups 
present a significant decrease in CMT maintained for up to 3 months [1, 21, 22, 24]. 
In group 3 two prospective randomized studies were included and summarized in table 
3 [26, 27]. These studies, including also patients with more severe conditions such as severe 
types of NPDR or PDR [26, 27] showed postoperative increase of BCVA and CMT during 
follow-up. Nevertheless, none of this changes presented statistically significant differences 
between IG (with both studies using bevacizumab) and CG [26, 27]. Despite that, patients 
subject to anti VEGF injection show statistically significant lower progression of diabetic 
retinopathy and diabetic maculopathy. 
In what concerns wet AMD, a total of six studies were included and summarized in table 
4 [28-33]. From these, five were retrospective case series and one was an open label prospective 
study. In all studies all patients were treated with anti-VEGF. However, in three studies patients 
were injected during surgery for active exudation [30, 32, 33], while in the other three studies 
eyes were treated with anti-VEGF in a perioperative basis in order to obtain an exudation free 
phase before surgery [28, 29, 31]. On the other hand, some studies injected patients with either 
bevacizumab or ranibizumab [28, 30, 31] , others with bevacizumab [32, 33] and another with 
ranibizumab [29]. In terms of visual acuity, all studies show a statistically significant 
improvement during follow-up [14, 28-32]. Still, no VA significant difference was found 
between patients in exudation free phase before surgery and the ones receiving intraoperative 
anti-VEGF therapy for active choroidal neovascular complex leakage [30]. On the other hand, 
differences between frequency of anti-VEGF injections before and after surgery achieved no 
statistically significance in [29, 31]. Despite that, patients with longer exudation free period 
before surgery and longer time between exudative AMD diagnosis and surgery, presented 
smaller recurrence of exudation after surgery [28]. In what concerns CMT, patients in exudation 
free phase before surgery presented statistically significant increase of CMT one month after 
surgery [29] and patients injected during surgery shown CMT decrease [32]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
All the recommendations presented in the following discussion should be put in 
perspective as their applicability depends on the chosen anti-VEGF agent. In other words, there 
is a big financial difference between applying bevacizumab as an adjuvant agent, which would 
add around 50$ to the cost of surgery, or to use ranibizumab or aflibercept with each dose 
costing around 2000$ [16]. Recently, aflibercept has been pointed to achieve slightly better VA 
in patients with diabetic retinopathy with greater vision loss [34] as well as in patients with wet 
AMD that do not respond to other anti-VEGF drugs [35]. However, at least in patients with wet 
AMD, benefits were considered modest and not cost-efficient compared with bevacizumab 
[16].  
Nevertheless, there are no studies comparing each of the anti-VEGF agents as adjuvant 
drugs in cataract surgery, reason why there is no clear indication of each of them is the best in 
this context. Also, there are no studies in which aflibercept was used peri-operatively or intra-
operatively. Moreover, we found no differences between results presented by studies using 
bevacizumab or ranibizumab, supporting that it is reasonable to think that bevacizumab is a 
valid and cheap option for adjuvant therapy in cataract surgery, as it can achieve similar 
outcomes as other drugs. 
 
Diabetic retinopathy and cataract surgery 
Evidence presented by articles in group 1 support that patients with NPDR without ME 
might benefit from adjuvant treatment with anti-VEGF as it is a safe procedure that reduces 
macular edema incidence even though it does not reflect in greater BCVA improvement during 
6 months follow-up. However, the lower ME incidence in IG may in a longer follow-up period 
translate into better VA outcomes considering the fact that macular edema is known to be the 
most important and common cause of central vision loss in diabetic patients [1]. Nevertheless, 
in study [19] in which patients with stable DR and with either no ME or mild ME were included, 
IG had statistically better BCVA at 6 months follow-up. However, the fact that patients with 
mild ME were included may be a cause of confusion and the reason why better BCVA 
improvement was seen in IG.  
In group 2, patients with DR and ME were also shown to benefit from cataract 
extraction, especially when combined with intravitreal anti-VEGF injection which show 
consistently greater VA improvement, along with significant decrease in CMT and ME. 
Although these CMT measurements should not directly evaluate a visual outcome, anatomic 
improvement in diabetic ME is known to be highly correlated with functional improvement in 
visual acuity [24] as also shown by Takamura, Kubo [22] in which there was statistical 
correlation between BCVA and CMT in both groups. Even though there is no class A evidence 
of efficacy for intravitreal anti-VEGF injection, this option should be taken into account 
seriously in cases in which patients with DME have cataract surgery. 
On the other hand, studies that included severe NPDR and PDR also contained patients 
with any other type of NPDR, reason why the results presented in group 3 reflect overall 
changes and not particularly patients with severe NPDR and PDR. For that reason, it is difficult 
to draw any conclusion whether this treatment should be performed in more advanced stages of 
DR. Nevertheless, there is at least theoretical benefit and it seems to be safe with no 
complications reported in these patients. 
 
Wet AMD and cataract surgery 
In what concerns patients with wet AMD, the combination of cataract extraction with 
adjuvant anti-VEGF agents appears to be beneficial and safe, as consistence VA gains were 
achieved without increased incidence of perioperative complications or macular adverse events. 
Moreover, frequency of injections is pointed to be the same before and after surgery, suggesting 
that phacoemulsification accompanied by operative or perioperative anti-VEGF injection does 
not increase exudation or change the characteristics of the underlying choroidal 
neovascularization. An exception to this statement was found in article [30] in which an 
intensive treatment and retreatment injection protocol ((PrONTO study protocol [36]) was 
implemented before surgery, resulting in a significantly lower injection frequency after surgery. 
However, this main difference with others studies can be justified by their intensive 
preoperative protocol which perhaps resulted in more patients in remission phase before 
surgery. On the other hand, it seems to be more beneficial to perform cataract extraction after 
longer exudation free periods in order to minimize exudation recurrence. However, specific 
guidelines are yet to be made. However, performing cataract surgery sooner may improve 
patient visual acuity faster and increase quality of life in an elderly population. Questions 
whether this adjuvant therapy should be used during surgery or in a perioperative basis or even 
which are the benefits comparing with other patients not receiving this treatment remain 
unclear. These questions can only be answered with clinical trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
Patients with NPDR with or without ME, benefit from anti-VEGF adjuvant treatment 
when subject to cataract surgery. However, evidence degree is higher for patients with ME in 
which an intraoperative anti-VEGF injection resulted in statistically significant better BCVA 
improvement. 
Indications for more severe retinal status, including severe NPDR and PDR remain 
unclear, without studies objectively addressing the question whether these particular patients 
benefit from cataract extraction with anti-VEGF adjuvant treatment. However, it should not be 
forgotten that it is a safe procedure with at least theoretical benefit for these patients. 
In what concerns patients with wet AMD, evidence lacks some support as no clinical 
trials were found, however, without reported complications it is fair to say that anti-VEGF 
treatments play an important role controlling exudation before and after surgery. For that 
reason, it is advisable to use this adjuvant treatment in wet AMD patients undergoing cataract 
surgery. Nevertheless, it is not clear which is the better approach. Whether promoting a more 
intensive treatment before surgery or injecting during surgery remains unanswered.  
In conclusion, we recommend the use of intraoperative bevacizumab in patients with 
DR and the intraoperative or perioperative use of this drug, according to retinal exudation status, 
for patients with wet AMD undergoing cataract surgery.  
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 Table 1 – Patients with DR and without ME 
                                           
Study 
 
Follow-up 
Results  
Complications Visual Acuity Outcomes Other outcomes 
Udaondo, Garcia-Pous [17] – 
Prospective Randomized Study 
 
Patients: 54 eyes in 54 patients 
with cataract and mild to 
moderate NPDR without 
macular edema preoperatively 
 
Intervention group (IG): 27 
eyes- intravitreal ranibizumab 
(0.5mL of solution at 10 mg/mL)  
at the 
end of phacoemulsification with 
IOL implantation 
 
Control group (CG): 27 eyes - 
phacoemulsification with IOL 
implantation 
3 months: 
 slit lamp examination 
of the anterior and 
posterior segment 
 Visual acuity with and 
without correction 
 Central macular 
thickness by OCT 
 IOP measurements  
 Incidence of CSME 
 
 
 
Preoperatively, 1 and 3 
months after surgery 
 Visual acuity outcomes 
were not specified. 
Central macular thickness: 
 Increased from baseline to month 1 (both 
groups) 
 Decreased from month 1 to month 3 (both 
groups) 
 
Incidence of CSME: 
 One month after surgery 
CG= 25.92%  
IG= 3.70%  
 
 Three months after surgery  
CG= 22.22% 
        IG=3.70% 
No complications 
were reported. 
Fard, Yazdanei Abyane [18] - 
prospective randomized study 
 
Patients: cataract patients with 
preexisting moderate or severe 
NPDR without ME having 
phacoemulsification and 
intraocular lens (IOL) 
implantation 
 
Intervention group (IG): 31 
eyes- received 1.25 mg of 
intravitreal bevacizumab at the 
end of phacoemulsification with 
IOL implantation 
6 months: 
 Best corrected visual 
acuity 
 Central macular 
thickness  
 Rate of DR 
progression 
 Rate of laser therapy 
after surgery 
 Macular edema 
incidence 
 IOP measurements 
 
 
 There was no 
statistically significant 
difference in 
postoperative visual 
acuity of both groups at 
6 months (P=0.3).´ 
Central Macular Thickness: 
 1 month after surgery: CG showed a significant 
increase (P=0.002) in CMT, whereas the IG did 
not show an increase.  
 
 6 months after surgery:  there was no 
significant difference in CMT between the two 
groups 
 
Progression of DR (6months): 
 CG:7 patients (23.3% of eyes) 
 IG: 5 patients (16.1% of eyes)   
(P=0.47, chi-square test) 
 
Rate of laser therapy: 
No complications 
were reported. 
 Control group (CG): 30 eyes - 
phacoemulsification with IOL 
implantation 
 
Preoperatively and 1 day, 4 
weeks, 3- and 4-months 
after surgery 
 There was no statistical difference between the 
2 groups  
(P=0.67, chi-square test).  
 
Macular edema incidence: 
 Lower incidence in IG at month 3 
 No differences in incidence between groups at 
month 6 
 No patients developed CSME. 
 
IOP: 
 There was no significant increase in intraocular 
pressure at 1 and 6 months after surgery in 
either group. 
 
Chae, Joe [19] – Prospective 
randomized study  
 
Patients: 80 eyes of 80 patients 
with significant cataract and 
NPDR with no or mild ME, 
underwent phacoemulsification 
and intraocular lens implantation 
 
Intervention group (IG): 40 
patients- intravitreal 
ranibizumab injection (0,05 ml 
of solution containing 0,5 mg of 
ranibizumab) combined with 
phacoemulsification and IOL 
implantation 
 
Control group (CG): 40 patients 
– phacoemulsification with IOL 
implantation 
6 months: 
 Best corrected visual 
acuities 
 Central subfield 
thickness 
 Total macular volume 
 ME occurrence 
(meaningful ME when 
CST increase 0.60 
relative to baseline) 
 
Baseline, 1 week, 1-, 3-, 6- 
months 
 No differences between 
groups at baseline, 1 
week, 1- and 3- month 
follow up visits 
 Greater BCVA 
improvement in IG at 6 
month follow up visit 
(P=0.046) 
Central Subfield Thickness relative to baseline: 
 Significantly lower in IG group at 1 week and 
1 month 
 No differences between groups at 3- and 6- 
months 
 
Total Macular Volume relative to baseline: 
 Increased in both groups 
 IG exhibited smaller change in TMV at all 
follow ups 
 The difference between the 2 groups was most 
significant at the 1-week follow-up visit (P < 
0.001) but remained significant at the 6-month 
visit (P = 0.017) 
 
ME Occurrence Rate (calculated by CST): 
 Significantly lower rate in IG at 1 month 
 No statistical differences at 3- and 6- months 
 
Comparison of Fluorescein Angiography Grading at 
3- and 6- months: 
 No statistical differences between groups 
Two adverse events: 
 IG: one 
vitreous 
hemorrhage 
 CG: one 
vitreous 
hemorrhage 
 
Table 2 - Patients with DR and ME  
                                           
Study 
 
Follow-up 
Results  
Complications Visual Acuity Outcomes Other outcomes 
Wahab and Ahmed [20] - 
prospective case series 
 
Patients: 38 patients with 
clinically significant macular 
edema, hypertension and 
diabetes (type II) were subjected 
to phacoemulsification and IOL 
implantation.  
 
All the patients had prior 
macular grid treatment and intra-
operative injection of intra-
vitreal Bevacizumab (Avastin) 
 
6 months: 
 Best corrected visual 
acuity 
 
 
 
 
 
 
Preoperatively and 1 day, 1 
week, and 1, 2, 3, and 6 
months after surgery 
 
Best corrected distant visual 
acuity of (6 months follow 
up): 
 6/6 to 6/9 in 23(60.5 %)  
 6/12 in 11(28.9%)  
 6/24 in 4(10.5%)  
 
Best corrected near acuity of 
(6 months follow up):  
 N/6 in 22(57.8%)  
 N/8 in 12(31.4%)  
 N/12 in 4(10.5%) 
 
Not studied. 
 
No complications 
were reported. 
Akinci, Batman [21] - case 
reports 
 
Patients: 31 patients with 
diabetes with CSME and 
cataract interfering with macular 
laser photocoagulation, who 
have undergone 
phacoemulsification with 
intravitreal injection of 1.25 mg 
bevacizumab.  
 
All eyes had undergone macular 
focal or modified grid laser 
photocoagulation 1 month after 
the surgery. 
 
3 months: 
 Best corrected visual 
acuity 
 Central macular 
thickness 
 IOP measurements 
 
Preoperatively and 1 day, 5 
days, 1 month, and 3 
months after the surgery. 
 
 The BCVA level 
recorded at the first and 
third months after the 
surgery were 
significantly higher 
than the initial BCVA 
(P = 0.004) 
 BCVA increased in all 
eyes and ≥2 Snellen 
lines gain in BCVA was 
achieved in 26 eyes. 
Central Macular Thickness: 
 CMT recorded at the first and third months 
after the surgery were significantly lower than 
the initial CMT (P < 0.001, P < 0.001). 
 Central macular thickness decreased in all 
eyes. 
 
IOP: 
 Postoperative IOP transient elevation was 
observed in 4 patients 
No complications 
were reported. 
Takamura, Kubo [22] - 
Prospective, randomized, double 
masked cohort study. 
3 months: 
 Best corrected visual 
acuity 
 Both groups had 
significant BCVA 
improvements. 
Retinal thickness: 
 1 and 3 months after surgery:  
CG: RT increased significantly  
No complications 
were reported. 
 Patients: 42 eyes with diabetic 
macular edema (DME) of 42 
patients with type 2 diabetes 
mellitus. Patients with PDR were 
excluded. 
 
Intervention group (IG): 21 eyes 
- received 1.25 mg of intravitreal 
bevacizumab at the 
end of phacoemulsification with 
IOL implantation 
 
Control group (CG): 21 eyes - 
phacoemulsification with IOL 
implantation 
 
 Retinal thickness 
 
Preoperatively (1 day 
before surgery), 1 – and 3 – 
months after surgery 
 
 VA in the bevacizumab 
group was significantly 
better at month 3 than 
in control group (P 
=0.034) 
 
 Improvement of BCVA 
(>3 line):  
IG: 15 eyes (71.4%)  
CG: 8 eyes (38.1%) 
 
IG: RT decreased significantly  
 
 3 months after surgery visual acuity and central 
RT were significantly correlated (ordinary 
least-squares regression analysis) in both the 
control group ( P = 0.0001) and the 
bevacizumab group (P = 0.014) 
Lanzagorta-Aresti, Palacios-
Pozo [23] - Prospective 
Randomized Study 
 
Patients: 26 type II diabetic 
patients with NPDR and diffuse 
macular edema undergoing 
cataract surgery 
 
Intervention group (IG): 13 eyes 
- received intravitreal 
bevacizumab at the end of 
phacoemulsification with IOL 
implantation 
 
Control group (CG): 13 eyes- 
received intravitreal with 
balanced salt solution at the end 
of phacoemulsification with IOL 
implantation  
 
6 months: 
 Best-corrected visual 
acuity 
 Central macular 
thickness 
 
Preoperatively, 3 and 6 
months after surgery 
Best-corrected visual acuity 
at 3 and 6 Months: 
 CG: no significant 
differences at month 3, 
with P= 0.528; visual 
acuity significant loss at 
month 6 (P=0.008) 
 IG: improved 
significantly at month 3 
and 6 (P=0.048; 
P=0.035) 
 
 There was statistically 
differences between 
both groups at month 3 
and 6 (P=0.036; 
P=0.046) 
Central macular thickness: 
 CG: significantly increased (P=0.001) 
 IG: no increase was observed 
 
There was statistically differences between both 
groups at month 3 and 6 (P=0.046; P=0.004) 
No complications 
were reported. 
Chen, Liu [24] – retrospective 
nonrandomized study 
 
Patients: 29 eyes of 28 diabetic 
patients with cataract and 
CSME. Patients with PDR were 
excluded. 
 
Intervention group (IG): 15 eyes 
- received intravitreal 2.5-mg 
bevacizumab at the end of 
phacoemulsification with IOL 
implantation  
 
Control group (CG): 14 eyes- 
phacoemulsification with IOL 
implantation 
 
3 months: 
 Best-corrected visual 
acuity  
 Central macular 
thickness 
 IOP measurements 
 
 
Preoperatively, day 1, 1-, 4-
, 8-, and 12 weeks, 3 
months after surgery. 
 CG: improved insignifi 
cantly at week 1 and 4 
(P>0.05) and 
significantly at week 8 
and 12. 
 
 IG: improved 
significantly at 1, 4, 8, 
and 12 weeks after 
surgery (P < 0.05)  
 
 
Central macular thickness: 
 CG: increased from baseline to week 4 and 
then decreased (P>0.05) 
 IG: decreased significantly at 4, 8, and 12 
weeks after surgery (P<0.05) 
 
IOP: 
 There was no increase in IOP 
No complications 
were reported. 
 
 
 
Table 3 - Patients with severe NPDR or PDR  
                                           
Study 
 
Follow-up 
Results  
Complications Visual Acuity Outcomes Other outcomes 
Salehi, Beni [26] - Prospective 
Randomized Study 
 
Patients: 57 eyes of 57 patients 
diagnosed with any type of  
NPDR or PDR, CSME and 
concurrent significant cataract 
 
Intervention group (IG): 27 
eyes- 1.25mg intravitreal 
bevacizumab at the end of 
phacoemulsification with IOL 
implantation 
 
Control group (CG): 30 eyes- 
phacoemulsification with IOL 
implantation 
6 months: 
 Best corrected visual 
acuity 
 Central macular 
thickness by OCT 
 Progression of DR and 
diabetic maculopathy 
 Postoperative laser 
therapy  
 Progression to 
neovascular glaucoma 
(NVG) 
 
 
 1 month after surgery: 
Both groups had 
statistically significant  
improvement of BCVA   
 
 6 months after surgery: 
no statistically 
significant difference in 
postoperative visual 
acuity between the 2 
groups 
Central Macular Thickness: 
 there was no significant difference between 
both groups concerning CMT at baseline and 6 
months 
 
Progression of Diabetic Retinopathy: 
 CG: 40% 
 IG: 11% 
 (P<0,005) 
 
Progression of diabetic maculopathy: 
 CG: 15 eyes (50%)  
 IG: 2 eyes (7.4%) 
 (P =0.0008) 
 
Postoperative laser therapy:  
 there was no statistical difference in the rate of 
laser therapy between groups. (laser therapy 
was used in – CSME and PDR) 
 
Progression to NVG during the follow-up:  
 CG: 5 eye (13%) 
 IG: 1 eye (3%) 
 
No complications 
were reported 
Cheema, Al-Mubarak [27] - 
prospective randomized study 
 
Patients: 68 eyes (68 patients) 
with DM and diabetic 
retinopathy (NPDR or PDR and 
CSME) undergoing cataract 
surgery and IOL implantation 
 
Intervention group (IG): 35 
eyes- received 1.25 mg of 
6 months: 
 progression of DR and 
diabetic maculopathy 
 Best-corrected visual 
acuity  
 central macular 
thickness 
 postoperative laser 
therapy 
 Improved in both 
groups. 
 
 There was no 
statistically significant 
difference in 
postoperative visual 
acuity at any time point 
between both groups. 
Central macular thickness:   
 increased in both groups 
 difference between groups was not statistically 
significant at any time 
 
Progression of DR: 
 CG: 45.45% 
 IG: 11.42% 
Difference between both groups was statistically 
significant (P=0.002) 
 
No complications 
were reported. 
intravitreal bevacizumab at the 
end of phacoemulsification with 
IOL implantation 
 
Control group (CG): 33 eyes - 
phacoemulsification with IOL 
implantation 
 
  progression to 
neovascular glaucoma 
(NVG) 
 
Preoperatively, 1 day, 1, 2, 
and 4 weeks, 2, 3, 4, 5, and 
6 months. 
Progression of DM: 
 CG: 51.51% 
 IG: 5.71% 
Difference between both groups was statistically 
significant (P=0.001) 
 
Laser photocoagulation was performed in: 
 CG: 48.48% 
 IG: 57.14% 
Difference between both groups was not statistically 
significant (P=0.475) 
 
Postoperative progression to NVG: 
 CG: 2 eyes 
 IG: 0 eyes 
 
 
 
Table 4 – Patients with wet AMD 
                                           
Study 
 
Follow-up 
Results  
Complications Visual Acuity Outcomes Other outcomes 
Lee, Kim [28] - retrospective, 
observational case series 
 
Patients: 39 eyes of 39 patients 
who underwent cataract surgery 
and had been previously treated 
with anti-VEGF (bevacizumab 
or ranibizumab) for exudative 
AMD.  
6 months:  
 Visual acuity 
 Exudative AMD 
recurrence 
 Time between 
exudative AMD 
diagnosis and surgery 
 Exudation-free period 
before surgery 
 
Preoperatively, 1- and 6-
months after surgery 
 
BCVA: 
 significantly improved 
1 and 6 months after 
surgery 
 
 
Time between exudative AMD diagnosis and 
surgery:  
 Recurrence group: 13.3±10.1 
 No recurrence group: 27.9±16.6 
 Statistically significant difference between 
groups (P= 0,001) 
 
Exudation-free period before surgery: 
 Recurrence group: 6.5±5.4 
 No recurrence group: 15.2±10.2 
 Statistically significant difference between 
groups (P< 0,001) 
 
 
No complications 
were reported. 
Grixti, Papavasileiou [29] - 
Retrospective, noncomparative, 
and interventional case series 
 
Patients: 30 eyes from 29 
subjects with neovascular AMD 
treated with intravitreal anti - 
VEGF injections (ranibizumab) 
who underwent 
phacoemulsification after 
achieving an exudation free 
phase of at least 3 months. 
6 months:  
 BCVA 
 Central macular 
thickness 
 Frequency of anti-
VEGF therapy 
 
Preoperatively; 1 month, 3 
months, and 6 months 
postoperatively 
BCVA: 
 Significant 
improvement at 3- and 
6-months follow up 
Central macular thickness: 
 increase between preoperative measurement 
and 1 month follow up (P=0.0093) 
 return to baseline at 3 months postoperatively 
(P=0.3811) 
 
 
Frequency of anti-VEGF injections: 
 no difference between the immediate 6 months 
before and after phacoemulsification 
 
 
No complications 
were reported. 
Tabandeh, Chaudhry [30] – Case 
series 
 
Patients: 30 eyes of 28 patients 
with occult or classic 
neovascular AMD treated by 
anti-VEGF (bevacizumab or 
ranibizumab) therapy before 
6 months:  
 BCVA 
 Frequency of anti 
– VEGF therapy 
Preoperatively, 2 and 6 
months after surgery. 
BCVA: 
 Statistically significant 
improvement at all 
postoperative time 
points compared to 
baseline 
 No significant 
difference in visual 
Frequency of anti – VEGF therapy: 
 Before surgery: 0,49 injections per month 
 After surgery: 0,32 injections per month 
 Statistically significant difference 
(P=0,002) 
 
No perioperative 
complications or 
macular adverse 
events were 
reported. 
 
cataract surgery. Some patients 
(8) received also an 
intraoperative injection. 
 
improvement between 
patients in a exudation 
free  phase before 
surgery and those who 
were receiving anti – 
VEGF therapy for 
active choroidal 
neovascular complex 
leakage 
 
Muzyka-Wozniak [31] - 
retrospective noncomparative 
interventional case-series study 
 
Patients: 16 eyes of 16 patients 
with choroidal neovascular 
AMD treated with anti – VEGF 
injections (bevacizumab or 
ranibizumab), undergoing 
phacoemulsification. 
 
14 months: 
 BCVA 
 Median time interval 
between injections  
 
Baseline (before first 
injection), immediately 
before surgery, 1 month 
after surgery, endpoint 
(median 14 months) 
BCVA:  
 Improved significantly 
after 
phacoemulsification 
and remained stable 
during follow-up  
Median time interval between injections: 
 There was no statistically significant difference 
before and after phacoemulsification 
 
 
Furino, Ferrara [32] – open label 
prospective study 
 
Patients: 20 eyes of 20 patients 
with subfoveal 
neovascularization due to AMD 
and cataract had 
phacoemulsification, IOL 
implantation and 1,25 mg 
intravitreal injection of 
bevacizumab 
 
1 month: 
 CDVA 
 Central retinal 
thickness 
 IOP 
 
 
Baseline and 1 month after 
surgery 
CDVA: 
 Statistically significant 
improvement  
 
Central retinal thickness: 
 Statistically significant reduction 
 No patient had an increase in central foveal 
thickness 
 
IOP:  
 did not change significantly 
 
 
 
No complications 
were reported 
Jonas, Spandau [33] – 
interventional case series study 
 
Patients: 11 eyes of 11 patients 
with exudative AMD (10 eyes) 
or exudative myopic macular 
   No complications 
were reported 
degeneration (1 eye) underwent 
phacoemulsification and 
intravitreal injection of 1.5mg 
bevacizumab 
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